Francis Rousseau
Keine laufenden Positionen mehr
Profil
Francis Rousseau worked as the Director of Genomics at IntegraGen SA from 2002 to 2012 and as the Genotyping Director at GenOdyssee SA. He holds a doctorate degree from Université Pierre et Marie Curie.
Ehemalige bekannte Positionen von Francis Rousseau
| Unternehmen | Position | Ende |
|---|---|---|
GenOdyssee SA
 GenOdyssee SA Miscellaneous Commercial ServicesCommercial Services GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of 'next generation' protein products for already developed blockbuster markets. The company has a proprietary genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have lead to the generation in the current population of unpredictable mutations that would confer superior therapeutic status to known human therapeutic proteins. | Corporate Officer/Principal | - |
| INTEGRAGEN | Corporate Officer/Principal | - |
Ausbildung von Francis Rousseau
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INTEGRAGEN | Health Services |
| Private Unternehmen | 2 |
|---|---|
| Université Pierre et Marie Curie | Consumer Services |
GenOdyssee SA
GenOdyssee SA Miscellaneous Commercial ServicesCommercial Services GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of 'next generation' protein products for already developed blockbuster markets. The company has a proprietary genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have lead to the generation in the current population of unpredictable mutations that would confer superior therapeutic status to known human therapeutic proteins. | Commercial Services |
